Protalix BioTherapeutics Inc. (NYSE:PLX) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 753,510 shares, a decline of 6.3% from the August 15th total of 804,122 shares. Based on an average daily trading volume, of 167,001 shares, the short-interest ratio is currently 4.5 days. Approximately 0.9% of the shares of the company are sold short.

A number of research firms have recently weighed in on PLX. Zacks Investment Research cut Protalix BioTherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 13th. Jefferies Group lowered their price objective on Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating on the stock in a research report on Tuesday, September 6th. Finally, Rodman & Renshaw reaffirmed a “buy” rating on shares of Protalix BioTherapeutics in a research report on Monday, July 11th.

Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 0.6004 on Wednesday. Protalix BioTherapeutics has a 52 week low of $0.58 and a 52 week high of $1.44. The company has a market cap of $59.89 million and a P/E ratio of 1.1866. The company’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.74.

Protalix BioTherapeutics (NYSE:PLX) last announced its earnings results on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The company earned $1.77 million during the quarter, compared to the consensus estimate of $1.34 million. During the same quarter in the prior year, the company earned ($0.05) earnings per share. Equities research analysts anticipate that Protalix BioTherapeutics will post ($0.41) earnings per share for the current fiscal year.

Protalix BioTherapeutics Company Profile

5 Day Chart for NYSE:PLX

Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.